Literature DB >> 11257022

Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant Streptococcus pneumoniae.

J P Maskell1, A M Sefton, L M Hall.   

Abstract

Trimethoprim resistance in Streptococcus pneumoniae can be conferred by a single amino acid substitution (I100-L) in dihydrofolate reductase (DHFR), but resistant clinical isolates usually carry multiple DHFR mutations. DHFR genes from five trimethoprim-resistant isolates from the United Kingdom were compared to susceptible isolates and used to transform a susceptible control strain (CP1015). All trimethoprim-resistant isolates and transformants contained the I100-L mutation. The properties of DHFRs from transformants with different combinations of mutations were compared. In a transformant with only the I100-L mutation (R12/T2) and a D92-A mutation also found in the DHFRs of susceptible isolates, the enzyme was much more resistant to trimethoprim inhibition (50% inhibitory concentration [IC50], 4.2 microM) than was the DHFR from strain CP1015 (IC50, 0.09 microM). However, Km values indicated a lower affinity for the enzyme's natural substrates (Km for dihydrofolate [DHF], 3.1 microM for CP1015 and 27.5 microM for R12/T2) and a twofold decrease in the specificity constant. In transformants with additional mutations in the C-terminal portion of the enzyme, Km values for DHF were reduced (9.2 to 15.2 microM), indicating compensation for the lower affinity generated by I100-L. Additional mutations in the N-terminal portion of the enzyme were associated with up to threefold-increased resistance to trimethoprim (IC50 of up to 13.7 microM). It is postulated that carriage of the mutation M53-I-which, like I100-L, corresponds to a trimethoprim binding site in the Escherichia coli DHFR-is responsible for this increase. This study demonstrates that although the I100-L mutation alone may give rise to trimethoprim resistance, additional mutations serve to enhance resistance and modulate the effects of existing mutations on the affinity of DHFR for its natural substrates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257022      PMCID: PMC90431          DOI: 10.1128/AAC.45.4.1104-1108.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Molecular epidemiology of drug-resistant pneumococci: toward an international approach.

Authors:  P W Hermans; M Sluijter; S Dejsirilert; N Lemmens; K Elzenaar; A van Veen; W H Goessens; R de Groot
Journal:  Microb Drug Resist       Date:  1997       Impact factor: 3.431

2.  Antimicrobial susceptibility of community-acquired bacterial lower respiratory tract pathogens.

Authors:  D Felmingham; M J Robbins; C Dencer; A Nathwani; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1996-10       Impact factor: 5.790

3.  Co-trimoxazole-resistant pneumococci.

Authors:  J G Howe; T S Wilson
Journal:  Lancet       Date:  1972-07-22       Impact factor: 79.321

4.  The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.

Authors:  D Felmingham; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  2000-02       Impact factor: 5.790

5.  Escherichia coli dihydrofolate reductase: isolation and characterization of two isozymes.

Authors:  D P Baccanari; D Averett; C Briggs; J Burchall
Journal:  Biochemistry       Date:  1977-08-09       Impact factor: 3.162

Review 6.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

7.  A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae.

Authors:  A Pikis; J A Donkersloot; W J Rodriguez; J M Keith
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

8.  Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance.

Authors:  J A Morris; R S McIvor
Journal:  Biochem Pharmacol       Date:  1994-03-29       Impact factor: 5.858

9.  Cloning and characterization of a novel, plasmid-encoded trimethoprim-resistant dihydrofolate reductase from Staphylococcus haemolyticus MUR313.

Authors:  G E Dale; H Langen; M G Page; R L Then; D Stüber
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Dihydrofolate reductase hysteresis and its effect of inhibitor binding analyses.

Authors:  D P Baccanari; S S Joyner
Journal:  Biochemistry       Date:  1981-03-31       Impact factor: 3.162

View more
  30 in total

1.  Escherichia coli mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections.

Authors:  Keith Miller; Alexander John O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

2.  Phenotypic and genotypic characterization of two penicillin-susceptible serotype 6B Streptococcus pneumoniae clones circulating in Italy.

Authors:  Giovanni Gherardi; Maria Del Grosso; Anna Scotto D'Abusco; Fabio D'Ambrosio; Giordano Dicuonzo; Annalisa Pantosti
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

Review 3.  Chemical space of Escherichia coli dihydrofolate reductase inhibitors: New approaches for discovering novel drugs for old bugs.

Authors:  Bharath Srinivasan; Sam Tonddast-Navaei; Ambrish Roy; Hongyi Zhou; Jeffrey Skolnick
Journal:  Med Res Rev       Date:  2018-09-07       Impact factor: 12.944

4.  Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis.

Authors:  Aimable Nahimana; Meja Rabodonirina; Jacques Bille; Patrick Francioli; Philippe M Hauser
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Targeted mutations of Bacillus anthracis dihydrofolate reductase condense complex structure−activity relationships.

Authors:  Jennifer M Beierlein; Nanda G Karri; Amy C Anderson
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

6.  Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim.

Authors:  Esther W Barrow; Philip C Bourne; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 7.  Antibacterial resistance.

Authors:  Jocelyn Y Ang; Elias Ezike; Basim I Asmar
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

8.  Kinetic and structural characterization of dihydrofolate reductase from Streptococcus pneumoniae.

Authors:  Jeeyeon Lee; Neela H Yennawar; Jongsik Gam; Stephen J Benkovic
Journal:  Biochemistry       Date:  2010-01-12       Impact factor: 3.162

9.  Trimethoprim resistance of dihydrofolate reductase variants from clinical isolates of Pneumocystis jirovecii.

Authors:  S F Queener; V Cody; J Pace; P Torkelson; A Gangjee
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

10.  Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.

Authors:  Christina R Bourne; Richard A Bunce; Philip C Bourne; K Darrell Berlin; Esther W Barrow; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.